2019
Qatar Pharma and Al Sulaiti v. Saudi Arabia Qatar Pharma for Pharmaceutical Industries , W.L.L. and Ahmed Bin Mohammad Al Haie Al Sulaiti v. Kingdom of Saudi Arabia (ICC Case No. 25830/AYZ/ELU)
Saudi Arabia
Qatar
Investments in two locally incorporated companies in the pharmaceutical industry and three warehouses for products in Riyadh, Jeddah and Dammam.
Claims arising out of the alleged repudiation of long-term sales contracts concluded between Saudi Arabia’s Ministry of Health and the claimants, after Saudi Arabia suspended diplomatic relations with Qatar in 2017. According to the claimants, the Ministry’s measures included a failure to pay for products supplied by the claimants under these contracts and allegedly forced them to close their warehouses in the country.
Secondary: C - Manufacturing
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
ICC (International Chamber of Commerce)
ICC (International Chamber of Commerce)
Fernández-Armesto, J.
Poncet, C.
Ziadé, N.
Decided in favour of investor
1352.40 mln QAR (362.22 mln USD)
360.20 mln QAR (96.50 mln USD)
Indirect expropriation

Fair and equitable treatment/Minimum standard of treatment, including denial of justice claims

Full protection and security, or similar

Umbrella clause

Most-favoured nation treatment

Transfer of funds

Arbitrary, unreasonable and/or discriminatory measures

Other
Fair and equitable treatment/Minimum standard of treatment, including denial of justice claims

Full protection and security, or similar

Most-favoured nation treatment

Arbitrary, unreasonable and/or discriminatory measures

Other
None